Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

Phase 2

• Conditions: Squamous NSCLC
• Interventions: Drug: Dovitinib

• Registration Number: NCT01861197
• Lead Sponsor: Samsung Medical Center

Brief Summary

Efficacy of Dovitinib for Squamous NSCLC.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-03
• Status Verified: 2013-05
• Study First Submitted: 2013-05-21
• Study First Submitted QC: 2013-05-22
• Last Update Submitted: 2013-05-22
• Study First Posted: 2013-05-23
• Last Update Posted: 2013-05-23
• Primary Completion: 2015-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

• histologically confirmed squamous NSCLC
• Previously treated with one or two lines of chemotherapy
• FGFR amplification (FISH > 5 copies of genes)
• 20 years or older
• ECOG PS 0-2

Exclusion Criteria

• active infection
• uncontrolled brain metastasis
• unstable angina or MI

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dovitinib monotherapy	Dovitinib	-

Primary Outcome Measures

Name	Time	Method
response rate	6 months

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of